Home » Business » Manufacturing
Pharmaceutical cash deal agreed
Source: Agencies |
June 18, 2013, Tuesday
|
Print Edition
Print Edition
JOHNSON & Johnson said yesterday it would buy Aragon Pharmaceuticals, a private company that is running a mid-stage clinical trial for a prostate cancer drug, for US$650 million in cash upfront and a possible second payment of US$350 million if it meets certain milestones.
The deal does not include development of Aragon's treatment for breast cancer, which will be spun off into a separate company called Seragon Pharmaceuticals ahead of the deal and will be run by Aragon's chief executive. The acquisition includes Aragon's most advanced drug, ARN-509, which is now being evaluated as a treatment for prostate cancer, it said.
The deal does not include development of Aragon's treatment for breast cancer, which will be spun off into a separate company called Seragon Pharmaceuticals ahead of the deal and will be run by Aragon's chief executive. The acquisition includes Aragon's most advanced drug, ARN-509, which is now being evaluated as a treatment for prostate cancer, it said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
